TG Therapeutics, Inc. (TGTX) Income Statement
TGTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTGTX revenue and net income
Where TGTX's revenue goes
2025Each bar shows an amount and its share of revenue. TGTX kept 72.6% of revenue as net income.
TGTX profit margins
TGTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +87.3% | +504.9% | +426.7% | +129.4% |
| Gross profit | +77.5% | +489.2% | +408.3% | +125.4% |
| Operating income | +194.1% | — | — | — |
| Net income | +1,812.4% | — | — | — |
| EPS (diluted) | +257.1% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TGTX quarterly EPS vs estimates
TG Therapeutics beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 2, 2026 (estimate $0.37).
TGTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M | $152,000 | $152,000 | $152,000 | $152,381 | $152,381 |
| Cost of revenue | $100.7M | $38.5M | $14.1M | $265,000 | $790,000 | $374,000 | $282,000 | $88,000 | $118.8M | $79.1M |
| Gross profit | $515.6M | $290.5M | $219.5M | $2.5M | $5.9M | $152,000 | $152,000 | $64,000 | $152,381 | $152,381 |
| Research & development | $160.2M | $94.3M | $76.2M | $125.4M | $222.6M | $165.9M | $154.2M | $153.8M | $96.9M | $66.5M |
| Sales, general & admin | $232.0M | $154.3M | $122.7M | $95.5M | $128.1M | $107.8M | $15.0M | $20.8M | $22.0M | $12.6M |
| Total operating expenses | $392.2M | $248.6M | $198.9M | $220.8M | $350.7M | $273.7M | $169.2M | $174.6M | $118.9M | $79.1M |
| Operating income | $123.3M | $41.9M | $20.6M | −$218.3M | −$344.8M | −$273.6M | −$169.1M | −$174.4M | −$118.7M | −$79.0M |
| Interest income | — | — | — | — | — | — | $5.3M | $857,000 | $294,478 | $323,032 |
| Interest expense | $26.7M | $24.0M | $12.6M | $10.2M | $5.6M | $6.3M | $5.3M | $1.7M | $1.1M | $0 |
| Income before taxes | $107.4M | $25.6M | $13.1M | −$223.8M | −$348.1M | −$279.4M | −$172.9M | −$173.5M | −$118.5M | −$78.3M |
| Income taxes | −$339.8M | $2.2M | $390,000 | $5.5M | $7.5M | $6.5M | $6.5M | −$918,000 | −$235,739 | −$716,234 |
| Net income | $447.2M | $23.4M | $12.7M | −$223.8M | −$348.1M | −$279.4M | −$172.9M | −$173.5M | −$118.5M | −$78.3M |
| EBITDA | $134.4M | $49.9M | $26.1M | −$213.1M | −$342.0M | −$272.7M | −$167.3M | −$173.4M | −$118.6M | −$78.9M |
| EPS (diluted) | $0.50 | $0.14 | $0.01 | −$1.46 | −$2.63 | −$2.40 | −$1.98 | −$2.30 | −$1.91 | −$1.59 |
| Gross margin | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | 100.0% | 100.0% | 42.1% | 100.0% | 100.0% |
| Operating margin | 20.0% | 12.7% | 8.8% | −7,839.0% | −5,154.3% | −179,996.1% | −111,220.4% | −114,736.8% | −77,904.6% | −51,823.5% |
| Net margin | 72.6% | 7.1% | 5.4% | −8,036.3% | −5,204.1% | −183,803.3% | −113,730.9% | −114,132.9% | −77,749.9% | −51,353.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $240.3M | $204.9M | $192.6M | $161.7M | $141.1M | $120.9M | $108.2M | $83.9M | $73.5M | $63.5M | $44.0M | $165.8M |
| Cost of revenue | $41.2M | $33.5M | $38.1M | $28.2M | $18.9M | $15.5M | $15.4M | $9.3M | $8.3M | $5.5M | $7.9M | $3.5M |
| Gross profit | $199.1M | $171.4M | $154.4M | $133.6M | $122.2M | $105.3M | $92.8M | $74.5M | $65.2M | $58.0M | $36.0M | $162.3M |
| Research & development | $95.3M | $48.4M | $41.2M | $40.9M | $31.8M | $46.4M | $23.9M | $20.1M | $17.6M | $32.7M | $17.4M | $14.8M |
| Sales, general & admin | $82.1M | $88.2M | $62.7M | $63.3M | $55.6M | $50.3M | $39.1M | $42.0M | $38.9M | $34.7M | $34.0M | $32.8M |
| Total operating expenses | $177.5M | $136.6M | $103.9M | $104.2M | $87.4M | $96.7M | $62.8M | $62.1M | $56.3M | $67.2M | $48.5M | $47.5M |
| Operating income | $21.7M | $34.8M | $50.5M | $29.4M | $34.8M | $8.6M | $29.9M | $12.4M | $8.8M | −$9.3M | −$12.5M | $114.8M |
| Interest expense | $16.6M | $7.7M | $6.5M | $6.7M | $6.7M | $6.8M | $7.1M | $10.8M | $4.0M | $2.3M | $2.4M | $3.7M |
| Income before taxes | $10.2M | $20.4M | $45.1M | $25.9M | $30.9M | $5.5M | $25.5M | $4.3M | $6.6M | −$10.7M | −$14.0M | $113.9M |
| Income taxes | $2.5M | $586,000 | $22.1M | −$365.0M | $2.7M | $408,000 | $2.1M | $388,000 | −$328,000 | $29,000 | $390,000 | −$126,000 |
| Net income | $7.8M | $19.8M | $23.0M | $390.9M | $28.2M | $5.1M | $23.3M | $3.9M | $6.9M | −$10.7M | −$14.4M | $113.9M |
| EBITDA | $21.8M | $28.1M | $51.7M | $32.7M | $37.7M | $12.3M | $32.6M | $15.2M | $10.6M | −$8.3M | −$11.5M | $117.8M |
| EPS (diluted) | $0.05 | $0.18 | $0.14 | $0.16 | $0.17 | $0.03 | $0.15 | $0.02 | $0.04 | −$0.07 | −$0.10 | $0.73 |
| Gross margin | 82.9% | 83.6% | 80.2% | 82.6% | 86.6% | 87.1% | 85.8% | 88.9% | 88.7% | 91.3% | 81.9% | 97.9% |
| Operating margin | 9.0% | 17.0% | 26.2% | 18.2% | 24.7% | 7.1% | 27.7% | 14.8% | 12.0% | −14.6% | −28.4% | 69.2% |
| Net margin | 3.2% | 9.7% | 12.0% | 241.7% | 20.0% | 4.2% | 21.6% | 4.6% | 9.4% | −16.9% | −32.8% | 68.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TGTX's financial statements (latest annual report filed February 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TGTX financial results
In fiscal year 2025 (ended December 31, 2025), TG Therapeutics reported revenue of $616.3 million, up 87.3% from the year before. It had net income of $447.2 million (up 1,812.4%), a net profit margin of 72.6%. Diluted earnings per share came to $0.50. Over five years revenue grew at an average rate of 426.7% a year.
See the TGTX stock overview for the latest quote and news, or the TGTX chart for price history and technical indicators.
TGTX income statement FAQ
What is TG Therapeutics's annual revenue?
TG Therapeutics reported total revenue of $616.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 87.3% from $329.0 million the previous year.
Is TG Therapeutics profitable?
Yes. TG Therapeutics reported net income of $447.2 million in fiscal 2025, a net profit margin of 72.6%; its operating margin was 20.0%.
What is TG Therapeutics's gross margin?
TG Therapeutics's gross margin was 83.7% in fiscal 2025: for every $100 of revenue, TG Therapeutics kept $84 after the direct cost of its products and services.
How much does TG Therapeutics spend on research and development?
TG Therapeutics spent $160.2 million on research and development in fiscal 2025, 26.0% of revenue.
How fast is TG Therapeutics growing?
Revenue grew 426.7% a year on average over the last five fiscal years, from $0.2 million to $616.3 million.
What are TG Therapeutics's earnings per share?
TG Therapeutics earned $0.50 per diluted share in fiscal 2025, compared with $0.14 a year earlier.
When will TG Therapeutics report its next earnings?
TG Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens.
When does TG Therapeutics's fiscal year end?
TG Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 27, 2026.